CellCept® (Mycophenolate Mofetil)
Lung Transplant Media Stories
PF Clinical Trials
Mycophenolate mofetil (MMF) is an effective and safe option for the management of systemic sclerosis–associated interstitial lung disease (SSc–ILD). In patients with SSc–ILD with declining pulmonary function, MMF therapy was associated with stability for up to 36 months. PubMed, Clin Exp Rheumatol, 03/24/2016.
Scleroderma Lung Study II. This study compares 2 different medications—daily oral cyclophosphamide (CYC) with daily oral mycophenolate mofetil (MMF, also called CellceptTM) in the treatment of scleroderma-related pulmonary fibrosis. There are twelve study centers across the U.S. University of California, Los Angeles. November 2009. (Also see Pulmonary Fibrosis, Cyclophosphamide, and Clinical Trials)
Shelley Ensz in Memory of Patricia Ann Black
Diana Kramer is reading Voices of Scleroderma book series!
Keith and Rosalyn Miller in Memory of Patricia Ann Black
Brenda Miller is Raising Awareness!
Susan Moore in Memory of Louise Beeler
Daniel and Joann Pepper in Memory of Gayle Hedlin
Vickie Risner is Raising Scleroderma Awareness!
Nancy Smithberg in Memory of Gayle Hedlin
David and Carleen Waterman in Memory of Gene Wilkinson
United Way of Central New Mexico
United Way of Snohomish County
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, Volunteer, or Donate.
International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content.